---
title: "J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297923035.md"
description: "J.P. Morgan analyst Salveen Richter reiterated a Buy rating on Teva Pharmaceutical with a $50 price target, citing successful Phase 2a results for TEV-408 in celiac disease and its potential as a 'pipeline-in-a-product.' The data shows meaningful protection against gluten injury without new safety concerns, suggesting broad therapeutic potential beyond celiac disease and vitiligo. This validates Teva's R&D execution and long-term growth outlook."
datetime: "2026-09-03T13:25:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297923035.md)
  - [en](https://longbridge.com/en/news/297923035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297923035.md)
generator: "portal-rs"
---

# J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

Teva Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Buy rating on the stock and has a $50.00 price target.

Salveen Richter has given his Buy rating due to a combination of factors tied to Teva’s emerging innovative pipeline and recent clinical progress. He views the new Phase 2a results for TEV-408 in celiac disease as a key validation point, showing meaningful protection against gluten-driven intestinal injury with no new safety concerns, in an area where approved therapies are lacking.

Richter also highlights that TEV-408 appears to have broad potential beyond celiac disease, building on earlier positive data in vitiligo and suggesting a pipeline-in-a-product profile that could differentiate Teva from competitors. He frames this data as part of Teva’s solid execution on an expanding R&D portfolio and a series of upcoming catalysts, which, in his view, improve the company’s long-term growth outlook even before IL-15 programs are explicitly reflected in his financial model.

According to TipRanks, Richter is a 5-star analyst with an average return of 13.4% and a 51.05% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Vertex Pharmaceuticals, and Moderna.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Teva to halt Phase II MSA therapy trial after futility analysis](https://longbridge.com/en/news/304098846.md)
- [Teva raises 2026 outlook for AUSTEDO, AJOVY and UZEDY after strong Q3 growth](https://longbridge.com/en/news/304116552.md)
- [Teva profit beats forecasts, raises 2026 revenue estimates](https://longbridge.com/en/news/304145598.md)
- [Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S. | TEVA Stock News](https://longbridge.com/en/news/304097001.md)
- [Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS](https://longbridge.com/en/news/304129112.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**